Leif Carlsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leif Carlsson has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Gunilla Linhardt
Bioscience Heart Failure, Cardiovascular Renal and Metabolism, IMED Biotech Unit AstraZeneca Gothenburg, Sweden
4 shared publicationsBirgit Andersson
Bioscience, AstraZeneca R&D Mölndal, Pepparedsleden 1, S-43183 Mölndal, Sweden
3 shared publicationsGöran Duker
AstraZeneca R&D, CVGI Innovative Medicine, Bioscience, Mölndal, Sweden
3 shared publicationsIngemar Jacobson
AstraZeneca R&D, CVGI Innovative Medicine, Bioscience, Mölndal, Sweden
3 shared publicationsLena Löfberg
2 shared publicationsAnders Berggren
AstraZeneca R&D, CVMD Innovative Medicine, Pepparedsleden 1, Mölndal S-43183, Sweden
1 shared publication
Latest Publications
- Open Access
- 15 January 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-7
Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo
Chemically modified mRNA is a novel, highly efficient, biocompatible modality for therapeutic protein expression that may overcome the challenges and safety concerns with current gene therapy strategies. We explored the efficiency of intradermally injected modified VEGF-A165 mRNA (VEGF-A mRNA) formulated in a biocompatible citrate/saline buffer to locally produce human VEGF-A165 protein. Rabbits (n=4) and minipigs (n=3) were implanted with subcutaneous microdialysis probes close to the injection sites and interstitial-fluid samples and skin biopsies were analysed for production of VEGF-A protein over time for up to 8 hours. Three to 4 hours after the intradermal injection of VEGF-A mRNA, detectable levels of human VEGF-A protein were seen in the microdialysis eluates in both species. In the pig, the VEGF-A concentrations increased dose-dependently reaching a maximum 6 hours after dosing (62.7±28.4, 357.6±240.6, and 746.3±210.2 pg/mL following injection of 24, 120, and 600 μg VEGF-A mRNA, respectively). Likewise, in tissue biopsies harvested at study end (8 hours after VEGF-A mRNA injection), the content of VEGF-A protein increased dose-dependently. In contrast, VEGF-A protein was not detected in eluates originating from sites injected with citrate/saline vehicle. It is concluded that intradermal injection of VEGF-A mRNA is associated with a rapid and local production of VEGF-A protein. Considering the pro-angiogenic effect of VEGF-A, VEGF-A mRNA may hold promise for regenerative treatment of patients with diabetic wounds and ischemic cardiovascular disease.
- 15 January 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-7
Open AccessRapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo
Chemically modified mRNA is a novel, highly efficient, biocompatible modality for therapeutic protein expression that may overcome the challenges and safety concerns with current gene therapy strategies. We explored the efficiency of intradermally injected modified VEGF-A165 mRNA (VEGF-A mRNA) formulated in a biocompatible citrate/saline buffer to locally produce human VEGF-A165 protein. Rabbits (n=4) and minipigs (n=3) were implanted with subcutaneous microdialysis probes close to the injection sites and interstitial-fluid samples and skin biopsies were analysed for production of VEGF-A protein over time for up to 8 hours. Three to 4 hours after the intradermal injection of VEGF-A mRNA, detectable levels of human VEGF-A protein were seen in the microdialysis eluates in both species. In the pig, the VEGF-A concentrations increased dose-dependently reaching a maximum 6 hours after dosing (62.7±28.4, 357.6±240.6, and 746.3±210.2 pg/mL following injection of 24, 120, and 600 μg VEGF-A mRNA, respectively). Likewise, in tissue biopsies harvested at study end (8 hours after VEGF-A mRNA injection), the content of VEGF-A protein increased dose-dependently. In contrast, VEGF-A protein was not detected in eluates originating from sites injected with citrate/saline vehicle. It is concluded that intradermal injection of VEGF-A mRNA is associated with a rapid and local production of VEGF-A protein. Considering the pro-angiogenic effect of VEGF-A, VEGF-A mRNA may hold promise for regenerative treatment of patients with diabetic wounds and ischemic cardiovascular disease.
- Open Access
- 31 July 2014
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 17 (3) , 473-482
Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans
We aimed at examining the acetylcholine-dependent inward-rectifier current (IKAch) as a target for the management of atrial fibrillation (AF). The investigative agents AZD2927 and A7071 concentration-dependently blocked IKAChin vitro with minimal off-target activity. In anaesthetized dogs (n = 17) subjected to 8 weeks of rapid atrial pacing (RAP), the left atrial effective refractory period (LAERP) was maximally increased by 50 ± 7.4 and 50 ± 4.8 ms following infusion of AZD2927 and A7071. Ventricular refractoriness and the QT interval were unaltered. During sustained AF, both drugs significantly reduced AF frequency and effectively restored sinus rhythm. AZD2927 successfully restored sinus rhythm at 10/10 conversion attempts and A7071 at 14/14 attempts, whereas saline converted 4/17 episodes only (Pn = 18) undergoing an invasive investigation, AZD2927 did not change LAERP, the paced QT interval, or ventricular refractoriness when compared with placebo. To address the discrepancy on LAERP by IKACh blockade in man and dog and the hypothesis that atrial electrical remodelling is a prerequisite for IKACh blockade being efficient, six dogs were studied after 8 weeks of RAP followed by sinus rhythm for 4 weeks to reverse electrical remodelling. In these dogs, both AZD2927 and A7071 were as effective in increasing LAERP as in the dogs studied immediately after the 8-week RAP period. Based on the present series of experiments, an important role of IKACh in human atrial electrophysiology, as well as its potential as a viable target for effective management of AF, may be questioned.
- 31 July 2014
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 17 (3) , 473-482
Open AccessIs the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans
We aimed at examining the acetylcholine-dependent inward-rectifier current (IKAch) as a target for the management of atrial fibrillation (AF). The investigative agents AZD2927 and A7071 concentration-dependently blocked IKAChin vitro with minimal off-target activity. In anaesthetized dogs (n = 17) subjected to 8 weeks of rapid atrial pacing (RAP), the left atrial effective refractory period (LAERP) was maximally increased by 50 ± 7.4 and 50 ± 4.8 ms following infusion of AZD2927 and A7071. Ventricular refractoriness and the QT interval were unaltered. During sustained AF, both drugs significantly reduced AF frequency and effectively restored sinus rhythm. AZD2927 successfully restored sinus rhythm at 10/10 conversion attempts and A7071 at 14/14 attempts, whereas saline converted 4/17 episodes only (Pn = 18) undergoing an invasive investigation, AZD2927 did not change LAERP, the paced QT interval, or ventricular refractoriness when compared with placebo. To address the discrepancy on LAERP by IKACh blockade in man and dog and the hypothesis that atrial electrical remodelling is a prerequisite for IKACh blockade being efficient, six dogs were studied after 8 weeks of RAP followed by sinus rhythm for 4 weeks to reverse electrical remodelling. In these dogs, both AZD2927 and A7071 were as effective in increasing LAERP as in the dogs studied immediately after the 8-week RAP period. Based on the present series of experiments, an important role of IKACh in human atrial electrophysiology, as well as its potential as a viable target for effective management of AF, may be questioned.
- 10 January 2013
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 18 (3) , 290-300
Electrophysiological Characterization and Antiarrhythmic Efficacy of the Mixed Potassium Channel-Blocking Antiarrhythmic Agent AZ13395438 In Vitro and In Vivo
Objective: To examine the electrophysiological, hemodynamic, and antiarrhythmic effects of the novel antiarrhythmic agent AZ13395438. Methods: The ion channel-blocking potency of AZ13395438 was assessed in Chinese hamster ovary cells stably expressing various human cardiac ion channels and in human atrial myocytes. The in vivo electrophysiological, hemodynamic, and antiarrhythmic effects of intravenously administered AZ13395438 were examined in anesthetized rabbits, in anesthetized naive dogs, and in dogs subjected to rapid atrial pacing (RAP) for 8 weeks. Pharmacokinetic/pharmacodynamic (PKPD) modeling was applied to predict the potency of AZ13395438 in increasing atrial and ventricular refractoriness. Results: AZ13395438 potently and predominantly blocked the atrial repolarizing potassium currents IKur, IAch, and Ito in vitro. In vivo, AZ13395438 caused a concentration-dependent and selective increase in atrial refractoriness with no or small effects on ventricular refractoriness and repolarization and on hemodynamics in both rabbits and dogs. The PKPD modeling predicted unbound plasma concentrations of AZ13395438 of 0.20 ± 0.039, 0.38 ± 0.084, and 0.34 ± 0.057 µmol/L to increase the right atrial effective refractory period by 20 milliseconds in the rabbit and in the naive and the RAP dogs, respectively. In the RAP dog with atrial fibrillation (AF), AZ13395438 significantly increased AF cycle length and successfully converted AF to sinus rhythm in 12 of the 12 occasions at an unbound plasma concentration of 0.48 ± 0.076 µmol/L. During saline infusion, conversion was seen only in 4 of the 10 occasions ( P = .003 vs AZ13395438). Furthermore, AZ13395438 reduced AF inducibility by burst pacing from 100% to 25% ( P < .001). Conclusion: AZ13395438 can be characterized as a mixed potassium ion channel-blocking agent that selectively prolongs atrial versus ventricular refractoriness and shows promising antiarrhythmic efficacy in a clinically relevant animal model of AF.
- 10 January 2013
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 18 (3) , 290-300
Electrophysiological Characterization and Antiarrhythmic Efficacy of the Mixed Potassium Channel-Blocking Antiarrhythmic Agent AZ13395438 In Vitro and In Vivo
Objective: To examine the electrophysiological, hemodynamic, and antiarrhythmic effects of the novel antiarrhythmic agent AZ13395438. Methods: The ion channel-blocking potency of AZ13395438 was assessed in Chinese hamster ovary cells stably expressing various human cardiac ion channels and in human atrial myocytes. The in vivo electrophysiological, hemodynamic, and antiarrhythmic effects of intravenously administered AZ13395438 were examined in anesthetized rabbits, in anesthetized naive dogs, and in dogs subjected to rapid atrial pacing (RAP) for 8 weeks. Pharmacokinetic/pharmacodynamic (PKPD) modeling was applied to predict the potency of AZ13395438 in increasing atrial and ventricular refractoriness. Results: AZ13395438 potently and predominantly blocked the atrial repolarizing potassium currents IKur, IAch, and Ito in vitro. In vivo, AZ13395438 caused a concentration-dependent and selective increase in atrial refractoriness with no or small effects on ventricular refractoriness and repolarization and on hemodynamics in both rabbits and dogs. The PKPD modeling predicted unbound plasma concentrations of AZ13395438 of 0.20 ± 0.039, 0.38 ± 0.084, and 0.34 ± 0.057 µmol/L to increase the right atrial effective refractory period by 20 milliseconds in the rabbit and in the naive and the RAP dogs, respectively. In the RAP dog with atrial fibrillation (AF), AZ13395438 significantly increased AF cycle length and successfully converted AF to sinus rhythm in 12 of the 12 occasions at an unbound plasma concentration of 0.48 ± 0.076 µmol/L. During saline infusion, conversion was seen only in 4 of the 10 occasions ( P = .003 vs AZ13395438). Furthermore, AZ13395438 reduced AF inducibility by burst pacing from 100% to 25% ( P < .001). Conclusion: AZ13395438 can be characterized as a mixed potassium ion channel-blocking agent that selectively prolongs atrial versus ventricular refractoriness and shows promising antiarrhythmic efficacy in a clinically relevant animal model of AF.
- 1 August 2010
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 31 (8) , 364-371
New pharmacological targets and treatments for atrial fibrillation
- 1 August 2010
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 31 (8) , 364-371
New pharmacological targets and treatments for atrial fibrillation
- Open Access
- 16 March 2010
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 12 (7) , 1003-1010
The combined ion channel blocker AZD1305 attenuates late Na current and IKr-induced action potential prolongation and repolarization instability
To assess the late Na + current ( INalate ) blockade by the combined ion channel blocker AZD1305 and its influence on repolarization liability in vitro . Blockade of INalate and the peak Na + current ( INapeak ) by AZD1305 and the effects of E-4031, AZD1305, and lidocaine on repolarization liability following cycle length (CL) changes were examined in dog cardiomyocytes and rabbit-superfused Purkinje fibre (PF) and ventricular muscle (VM) preparations, respectively. In the rabbit preparations, a short–long–short CL sequence was introduced during, and followed by, stimulation at a basic CL of 500 ms in the presence of E-4031, AZD1305, E-4031 + AZD1305, or E-4031 + lidocaine. The standard deviation of the action potential duration at 90% repolarization (APD 90 ) of the five action potentials following resumption of the basic CL was quantified as APD 90 instability. AZD1305 concentration-dependently blocked INalate (IC 50 = 4.3 µM) and INapeak (IC 50 = 66 µM). In PFs, E-4031, but not AZD1305, markedly prolonged APD 90 (from 380 ± 15 to 597 ± 86 ms, P < 0.05) after the long CL and augmented APD 90 instability (2 ± 0.4 to 24 ± 6.1 ms, P < 0.05), increases significantly attenuated by AZD1305 and lidocaine. In the VM, the APD 90 prolongation by E-4031 was quantitatively much smaller, thus augmenting the repolarization heterogeneity between the PF and VM, an increase markedly reduced by AZD1305 and lidocaine. By blocking INalate , AZD1305 attenuates excessive APD 90 prolongation and repolarization instability following sudden slowing of rhythm implying a low proarrhythmic potential for AZD1305.
- 16 March 2010
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 12 (7) , 1003-1010
Open AccessThe combined ion channel blocker AZD1305 attenuates late Na current and IKr-induced action potential prolongation and repolarization instability
To assess the late Na + current ( INalate ) blockade by the combined ion channel blocker AZD1305 and its influence on repolarization liability in vitro . Blockade of INalate and the peak Na + current ( INapeak ) by AZD1305 and the effects of E-4031, AZD1305, and lidocaine on repolarization liability following cycle length (CL) changes were examined in dog cardiomyocytes and rabbit-superfused Purkinje fibre (PF) and ventricular muscle (VM) preparations, respectively. In the rabbit preparations, a short–long–short CL sequence was introduced during, and followed by, stimulation at a basic CL of 500 ms in the presence of E-4031, AZD1305, E-4031 + AZD1305, or E-4031 + lidocaine. The standard deviation of the action potential duration at 90% repolarization (APD 90 ) of the five action potentials following resumption of the basic CL was quantified as APD 90 instability. AZD1305 concentration-dependently blocked INalate (IC 50 = 4.3 µM) and INapeak (IC 50 = 66 µM). In PFs, E-4031, but not AZD1305, markedly prolonged APD 90 (from 380 ± 15 to 597 ± 86 ms, P < 0.05) after the long CL and augmented APD 90 instability (2 ± 0.4 to 24 ± 6.1 ms, P < 0.05), increases significantly attenuated by AZD1305 and lidocaine. In the VM, the APD 90 prolongation by E-4031 was quantitatively much smaller, thus augmenting the repolarization heterogeneity between the PF and VM, an increase markedly reduced by AZD1305 and lidocaine. By blocking INalate , AZD1305 attenuates excessive APD 90 prolongation and repolarization instability following sudden slowing of rhythm implying a low proarrhythmic potential for AZD1305.
- 1 July 2009
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 54 (1) , 82-89
Assessment of the Ion Channel-blocking Profile of the Novel Combined Ion Channel Blocker AZD1305 and Its Proarrhythmic Potential Versus Dofetilide in the Methoxamine-sensitized Rabbit In Vivo
AZD1305 is a novel antiarrhythmic agent under clinical evaluation for management of atrial fibrillation. This study assessed its ion channel-blocking potency by the whole cell patch-clamp technique in vitro and its proarrhythmic liability in anesthetized methoxamine-sensitized rabbits in comparison with dofetilide. AZD1305 predominantly blocked the hERG, the L-type calcium and the hNav1.5 currents in a concentration-dependent manner. In vivo AZD1305 increased the QT interval (from 145 +/- 8 to 196 +/- 18 ms, P < 0.01) without inducing ventricular extrasystoles or torsades de pointes (TdP). In contrast, dofetilide prolonged the QT interval from 161 +/- 3 to 256 +/- 15 ms (P < 0.001) and caused TdP in 12/17 rabbits (P < 0.01 vs. AZD1305). During AZD1305 and dofetilide infusion, the QTend-peak interval maximally increased by 14 +/- 4 and 30 +/- 6 ms (P < 0.05 vs. AZD1305) and the beat-by-beat QT interval variability (quantified as the short-term variability, STV) changed from 2 +/- 0.8 to 2 +/- 0.3 ms (NS) and from 2 +/- 0.2 to 12 +/- 1.1 ms (P < 0.001), respectively. Following dofetilide-induced TdP, 6 rabbits each were injected with saline or AZD1305. In contrast to saline, AZD1305 abbreviated the QT interval (from 275 +/- 25 to 216 +/- 9 ms, P < 0.05), reduced the STV to 1 +/- 0.1 ms (P < 0.001) and suppressed TdP in all 6 rabbits (P < 0.01 vs. saline). In conclusion, AZD1305 can be characterised as a combined ion channel blocker that delays repolarization without increasing beat-by-beat variability of repolarization (BVR) or inducing TdP whereas selective IKr blockade by dofetilide prolongs the QT interval and eventually increases BVR resulting in TdP.
- 1 July 2009
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 54 (1) , 82-89
Assessment of the Ion Channel-blocking Profile of the Novel Combined Ion Channel Blocker AZD1305 and Its Proarrhythmic Potential Versus Dofetilide in the Methoxamine-sensitized Rabbit In Vivo
AZD1305 is a novel antiarrhythmic agent under clinical evaluation for management of atrial fibrillation. This study assessed its ion channel-blocking potency by the whole cell patch-clamp technique in vitro and its proarrhythmic liability in anesthetized methoxamine-sensitized rabbits in comparison with dofetilide. AZD1305 predominantly blocked the hERG, the L-type calcium and the hNav1.5 currents in a concentration-dependent manner. In vivo AZD1305 increased the QT interval (from 145 +/- 8 to 196 +/- 18 ms, P < 0.01) without inducing ventricular extrasystoles or torsades de pointes (TdP). In contrast, dofetilide prolonged the QT interval from 161 +/- 3 to 256 +/- 15 ms (P < 0.001) and caused TdP in 12/17 rabbits (P < 0.01 vs. AZD1305). During AZD1305 and dofetilide infusion, the QTend-peak interval maximally increased by 14 +/- 4 and 30 +/- 6 ms (P < 0.05 vs. AZD1305) and the beat-by-beat QT interval variability (quantified as the short-term variability, STV) changed from 2 +/- 0.8 to 2 +/- 0.3 ms (NS) and from 2 +/- 0.2 to 12 +/- 1.1 ms (P < 0.001), respectively. Following dofetilide-induced TdP, 6 rabbits each were injected with saline or AZD1305. In contrast to saline, AZD1305 abbreviated the QT interval (from 275 +/- 25 to 216 +/- 9 ms, P < 0.05), reduced the STV to 1 +/- 0.1 ms (P < 0.001) and suppressed TdP in all 6 rabbits (P < 0.01 vs. saline). In conclusion, AZD1305 can be characterised as a combined ion channel blocker that delays repolarization without increasing beat-by-beat variability of repolarization (BVR) or inducing TdP whereas selective IKr blockade by dofetilide prolongs the QT interval and eventually increases BVR resulting in TdP.
- 1 August 2008
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 119 (2) , 160-167
The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes
- 1 August 2008
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 119 (2) , 160-167
The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes
- Open Access
- 1 July 2006
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 8 (7) , 549-557
Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro
Aims To compare the electrophysiological and antiarrhythmic effects of AZD7009, azimilide, and AVE0118 in the acutely dilated rabbit atria in vitro. Methods and results In the isolated Langendorf-perfused rabbit heart, the atrial effective refractory period (AERP) and the inducibility of atrial fibrillation (AF) were measured at increasing concentrations of AZD7009 (0.1–3 µM), azimilide (0.1–3 µM), and AVE0118 (0.3–10 µM). In separate groups of atria, termination of sustained AF was assessed. In non-dilated atria, the AERP was 82±1.3 ms (mean±SEM) and AF could not be induced. Dilation significantly reduced the AERP to 49±1.0 ms (PPPPPConclusion In the dilated rabbit atria, AZD7009, azimilide, and AVE0118 concentration-dependently increased AERP, effectively prevented AF induction, and rapidly restored sinus rhythm.
- 1 July 2006
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 8 (7) , 549-557
Open AccessElectrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro
Aims To compare the electrophysiological and antiarrhythmic effects of AZD7009, azimilide, and AVE0118 in the acutely dilated rabbit atria in vitro. Methods and results In the isolated Langendorf-perfused rabbit heart, the atrial effective refractory period (AERP) and the inducibility of atrial fibrillation (AF) were measured at increasing concentrations of AZD7009 (0.1–3 µM), azimilide (0.1–3 µM), and AVE0118 (0.3–10 µM). In separate groups of atria, termination of sustained AF was assessed. In non-dilated atria, the AERP was 82±1.3 ms (mean±SEM) and AF could not be induced. Dilation significantly reduced the AERP to 49±1.0 ms (PPPPPConclusion In the dilated rabbit atria, AZD7009, azimilide, and AVE0118 concentration-dependently increased AERP, effectively prevented AF induction, and rapidly restored sinus rhythm.
- 29 November 2005
- Published by Wiley in Journal of Internal Medicine
- Vol. 259 (1) , 70-80
In vitroandin vivomodels for testing arrhythmogenesis in drugs
: The steadily increasing list of drugs associated with prolongation of the QT interval and torsades de pointes (TdP) constitute a medical problem of major concern. Hence, there is a need at an early stage to identify drug candidates with an inherent capacity to induce repolarization‐related proarrhythmias, avoiding exposure of large populations to potentially harmful drugs. Furthermore, the availability of clinically relevant and predictive animal models should reduce the risk that effective and potentially life‐saving drugs never reach the market. This review will discuss the pros and cons of somein vivoandin vitroanimal models for assessing proarrhythmia liability.
- 29 November 2005
- Published by Wiley in Journal of Internal Medicine
- Vol. 259 (1) , 70-80
In vitroandin vivomodels for testing arrhythmogenesis in drugs
: The steadily increasing list of drugs associated with prolongation of the QT interval and torsades de pointes (TdP) constitute a medical problem of major concern. Hence, there is a need at an early stage to identify drug candidates with an inherent capacity to induce repolarization‐related proarrhythmias, avoiding exposure of large populations to potentially harmful drugs. Furthermore, the availability of clinically relevant and predictive animal models should reduce the risk that effective and potentially life‐saving drugs never reach the market. This review will discuss the pros and cons of somein vivoandin vitroanimal models for assessing proarrhythmia liability.
- 6 June 2003
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 14 (6) , 651-658
Block of HERG‐Carried K+ Currents by the New Repolarization Delaying Agent H 345/52
The aim of this study was to analyze the block of HERG-carried membrane currents caused by H 345/52, a new antiarrhythmic compound with low proarrhythmic activity, in transfected mouse fibroblasts. Using the whole-cell configuration of the voltage patch clamp technique, it was demonstrated that H 345/52 concentration-dependently blocked HERG-carried currents with an IC50 of 230 nM. H 345/52 preferentially bound to the open channel with unusually rapid kinetics and was trapped by channel closure. Voltage-independent behavior of H 345/52 was observed during both square-pulse and action potential clamp protocols. In contrast, the Class III agents dofetilide (10 nM) and almokalant (250 nM) demonstrated significant membrane potential-dependent effects during square-pulse clamp protocols. When using action potential clamp protocols, voltage dependence was seen with dofetilide but not with almokalant. Mathematical simulations of human ventricular action potentials predicted that the different voltage-dependent behaviors would not produce marked variations in action potential duration prolongation patterns. We propose that block of IKr is the principal mechanism by which H 345/52 delays repolarization in human myocardium. The voltage independence of HERG/IKr block is unlikely to underlie the low proarrhythmic potential, and ancillary effects on other membrane currents must be considered.
- 6 June 2003
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 14 (6) , 651-658
Block of HERG‐Carried K+ Currents by the New Repolarization Delaying Agent H 345/52
The aim of this study was to analyze the block of HERG-carried membrane currents caused by H 345/52, a new antiarrhythmic compound with low proarrhythmic activity, in transfected mouse fibroblasts. Using the whole-cell configuration of the voltage patch clamp technique, it was demonstrated that H 345/52 concentration-dependently blocked HERG-carried currents with an IC50 of 230 nM. H 345/52 preferentially bound to the open channel with unusually rapid kinetics and was trapped by channel closure. Voltage-independent behavior of H 345/52 was observed during both square-pulse and action potential clamp protocols. In contrast, the Class III agents dofetilide (10 nM) and almokalant (250 nM) demonstrated significant membrane potential-dependent effects during square-pulse clamp protocols. When using action potential clamp protocols, voltage dependence was seen with dofetilide but not with almokalant. Mathematical simulations of human ventricular action potentials predicted that the different voltage-dependent behaviors would not produce marked variations in action potential duration prolongation patterns. We propose that block of IKr is the principal mechanism by which H 345/52 delays repolarization in human myocardium. The voltage independence of HERG/IKr block is unlikely to underlie the low proarrhythmic potential, and ancillary effects on other membrane currents must be considered.